# Solid Tumor Therapeutics

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN DIEGO · 2021 · $32,087

## Abstract

SOLID TUMOR THERAPEUTICS ABSTRACT
The overall goal of Solid Tumor Therapeutics (STT) is to develop novel therapeutics and strategies for the
treatment of non-hematologic malignancies and to advance the diagnostic and biomarker tools needed to
individualize their use. As a result, STT directly supports the mission, vision, and strategic priorities of MCC,
which has prioritized exploiting MCC’s discoveries to maximize our ability to tailor cancer care plans based on
each patient’s personal profile. The 59 members of STT come from diverse disciplines but are joined together
by their shared research interest in solid tumor biology and treatment. Reflecting this, members are drawn from
16 departments and 4 schools. In 2017, program members had a total of $22.3M (direct costs) in cancer-focused
funding. $13.0M (direct costs) is peer-reviewed funding, of which $6.0M (46%) was from NCI, $3.9M (30%) was
from other NIH sources, and $3.0M (23%) was from other peer-reviewed agencies. During the project period,
members authored 1662 cancer-relevant publications, of which 255 (15%) were intra-programmatic, 295 (18%)
were inter-programmatic, and 485 (29%) were collaborative with investigators from other NCI-designated cancer
centers. STT members also led 64 early phase investigator-initiated trials (IITs), which include translation of 20
of MCC’s scientific discoveries to the clinic through 26 IITs, a 13-fold increase over 2 such IITs between 2008-
2012. Accrual to STT treatment IITs increased by 218%, from 223 (2008-2012) to 709 (2013-2017). STT’s
specific aims are to: 1) Identify tumor vulnerabilities, mechanisms, and targetable alterations; 2) Develop new
classes of therapeutics and delivery systems; 3) Develop novel technologies to detect tumors and define tumor
geography, microenvironment, and exploitable metabolic and signaling defects; and 4) Establish the clinical
benefit of novel therapeutics and genome-driven treatment strategies. The cross-cutting themes are: A) Immune
Oncology; B) Cancer Stem Cells, and C) Patient-specific Precision Therapy. STT is co-led by Ezra Cohen, MD,
an expert in head and neck cancer and the clinical application of immune oncology discoveries; and Jeremy
Rich, MD, MHS, MBA, whose career has focused on cancer stem cells and brain tumors. Their highly integrated
efforts foster collaboration among the outstanding investigators in STT, who are leaders in their fields and have
track records of extraordinary productivity.

## Key facts

- **NIH application ID:** 10160799
- **Project number:** 5P30CA023100-35
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN DIEGO
- **Principal Investigator:** Ezra Cohen
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $32,087
- **Award type:** 5
- **Project period:** 1996-07-01 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10160799

## Citation

> US National Institutes of Health, RePORTER application 10160799, Solid Tumor Therapeutics (5P30CA023100-35). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10160799. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*